Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. by Raymond K Cross, Michael Chiorean, Francis Vekeman, Yongling Xiao, Eric Wu, Jingdong Chao, Anthony W Wang

Get full text

Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need From the CorEvitas Inflammatory Bowel Disease Registry by Douglas C. Wolf, April N. Naegeli, Page C. Moore, Jud C. Janak, Margaux M. Crabtree, Mingyang Shan, Theresa M. Hunter, Angelina Sontag, Raymond K. Cross

Get full text

ExpLOring the role of the intestinal MiCrobiome in InflammATory bowel disease-AssocIated SpONdylarthritis (LOCATION-IBD) by Madeline Alizadeh, Uni Wong, Bernadette C. Siaton, Seema A. Patil, Lauren George, Jean-Pierre Raufman, William H. Scott, Erik C. von Rosenvinge, Jacques Ravel, Raymond K. Cross

Get full text

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease by Byron P. Vaughn, Andres J. Yarur, Elliot Graziano, James P. Campbell, Abhik Bhattacharya, Jennifer Y. Lee, Katherine Gheysens, Konstantinos Papamichael, Mark T. Osterman, Adam S. Cheifetz, Raymond K. Cross

Get full text

Poor Patient-Reported Outcomes and Impaired Work Productivity in Patients With Inflammatory Bowel Disease in Remission by Raymond K. Cross, Jenny S. Sauk, Joe Zhuo, Ryan W. Harrison, Samantha J. Kerti, Kelechi Emeanuru, Jacqueline O’Brien, Harris A. Ahmad, Antoine G. Sreih, Joehl Nguyen, Sara N. Horst, David Hudesman

Get full text

Multicenter Study of Nonadherence to Self-Injectable Biologic Therapy in Patients With Inflammatory Bowel Disease: Risk Factors and Outcomes by Lauren A. George, Erin Causey, Nisha B. Shah, James C. Slaughter, Jonah Jerabek, Autumn D. Zuckerman, Susan Chhen, Elizabeth Scoville, Robin Dalal, Dawn B. Beaulieu, Baldeep Pabla, David A. Schwartz, Raymond K. Cross, Byron P. Vaughn, Sara Horst

Get full text